Cancer Letters : Impact Factor & More
eISSN: 1872-7980pISSN: 0304-3835
Share this on:
Aims and Scope of Cancer Letters
Cancer Letters is a peer-reviewed medical journal established in 1975 that focuses on the rapid publication of original research on multidisciplinary aspects of cancer. The editor-in-chief is M. Schwab. Less
Key Metrics
CiteScore 
16.1
Eigenfactor
0.01 - 0.05
H-Index
203
Impact Factor
5 - 10
Scite Index
0.93 5-Year SI
SJR
Q1Oncology
SNIP
1.69
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Cancer Letters
Cancer Letters Journal Specifications
| Overview | |
| Publisher | ELSEVIER IRELAND LTD |
| Language | English |
| Frequency | Fortnightly |
| General Details | |
| Language | English |
| Frequency | Fortnightly |
| Publication Start Year | 1975 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Cancer Letters ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Cancer Letters
Optimized L1CAM-CAR T cells enhance activity against moderate-antigen-density rhabdomyosarcoma models.
- 1 Oct 2026
- Cancer letters
Engineered multivalent VCAM1-Fc decoys remodel ECM mechanosensing to suppress H3K18la-driven epigenetic programs and stemness in recurrent glioblastoma.
- 1 Oct 2026
- Cancer letters
Mechano-activation of osteocytic connexin hemichannels prime microenvironment in suppressing breast cancer bone metastasis.
- 1 Oct 2026
- Cancer letters
T-cell receptor-engineered T-cell therapy using a glypican-3-specific TCR derived from a hepatoblastoma vaccine responder for HLA-A2-positive glypican-3-expressing cancers.
- 1 Oct 2026
- Cancer letters
Targeting MDA-9/syntenin-1 (SDCBP) as a strategy to eliminate head and neck squamous cell carcinoma stem cells.
- 1 Oct 2026
- Cancer letters
Orthogonally targeted tumor radiosensitization using cell penetrating peptide-ATM inhibitor conjugates to stimulate anti-tumor immune responses.
- 1 Oct 2026
- Cancer letters
Optimized L1CAM-CAR T cells enhance activity against moderate-antigen-density rhabdomyosarcoma models.
- 1 Oct 2026
- Cancer letters
Engineered multivalent VCAM1-Fc decoys remodel ECM mechanosensing to suppress H3K18la-driven epigenetic programs and stemness in recurrent glioblastoma.
- 1 Oct 2026
- Cancer letters
Mechano-activation of osteocytic connexin hemichannels prime microenvironment in suppressing breast cancer bone metastasis.
- 1 Oct 2026
- Cancer letters
T-cell receptor-engineered T-cell therapy using a glypican-3-specific TCR derived from a hepatoblastoma vaccine responder for HLA-A2-positive glypican-3-expressing cancers.
- 1 Oct 2026
- Cancer letters
Targeting MDA-9/syntenin-1 (SDCBP) as a strategy to eliminate head and neck squamous cell carcinoma stem cells.
- 1 Oct 2026
- Cancer letters
Orthogonally targeted tumor radiosensitization using cell penetrating peptide-ATM inhibitor conjugates to stimulate anti-tumor immune responses.
- 1 Oct 2026
- Cancer letters
FAQs on Cancer Letters
How long has Cancer Letters been actively publishing? 
What is the publishing frequency of Cancer Letters?
How many articles did Cancer Letters publish last year?
What is the eISSN & pISSN for Cancer Letters?
What is Citescore for Cancer Letters?
What is the H Index for Cancer Letters ?
What is SNIP score for Cancer Letters?
What is the SJR for Cancer Letters?
Who is the publisher of Cancer Letters?
